FDA Grants Breakthrough Device Designation To Seastar Medical's Selective Cytopheretic Device For Cardiorenal Syndrome

  • Kevin Chung

Press/Media

Period29 Sep 2023

Media coverage

1

Media coverage

  • TitleFDA Grants Breakthrough Device Designation To Seastar Medical's Selective Cytopheretic Device For Cardiorenal Syndrome
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date29/09/23
    PersonsKevin Chung
View all 1
View less